Avidin submitted a patent application on novel quinoline analogues which may have potential applications in anxiety disorders and Alzheimer’s disease (AD). The IP held by Avidin on the novel structure and its application is valuable, offering the possibility of widening the application of the drug candidate.

Avidin optimized its toxicogenomics and ADME/Tox gene expression analysis platform.

During toxicogenomics screening relative expression alterations in marker genes from heart, brain, liver and kidney samples are determined from drug treated mice vs. control animals.